Is EXEL a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Cabozantinib franchise growth, with revenue (ttm) at ~$2.2 billion (Q1 2026 total revenue was ~$611 million, up ~10% year over year). The bear case rests on the dominant risk is single-franchise concentration: the large majority of revenue comes from cabozantinib, so any competitive, safety, or reimbursement setback in kidney cancer would hit the whole company. Analysts covering it are spread from $41.00 to $64.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is single-franchise concentration: the large majority of revenue comes from cabozantinib, so any competitive, safety, or reimbursement setback in kidney cancer would hit the whole company. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $41.00, -27.1% from the $56.25 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Cabozantinib franchise growth. Cabozantinib remains the growth engine, with Q1 2026 cabozantinib franchise net product revenue of about $555 million and continued share gains as the leading TKI in second-line-plus kidney cancer and the oral market leader in neuroendocrine tumors. The most optimistic analyst target on EXEL is $64.00, +13.8% from the $56.25 price. That figure is only reachable if this thesis works close to its best case.

The dominant risk is single-franchise concentration: the large majority of revenue comes from cabozantinib, so any competitive, safety, or reimbursement setback in kidney cancer would hit the whole company. Cabozantinib faces a patent cliff and generic competition risk later this decade (litigation has delayed but not removed it), which makes the zanzalintinib transition critical and time-sensitive. Pipeline risk is real, as trials can miss endpoints or draw a narrow label, and Exelixis has already discontinued some zanzalintinib programs such as head and neck cancer. Regulatory timing, including the roughly December 2026 colorectal decision, can slip. Competition in kidney and colorectal cancer from large pharma and other TKIs and immunotherapies is intense, and the stock can move sharply on binary clinical and regulatory news. The most pessimistic published target is $41.00, -27.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Exelixis, Inc.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Cabozantinib franchise growth) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is single-franchise concentration: the large majority of revenue comes from cabozantinib, so any competitive, safety, or reimbursement setback in kidney cancer would hit the whole company) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a growing, profitable cabozantinib franchise, a strong cash position with buybacks, and a promising successor drug in zanzalintinib heading toward a late-2026 colorectal decision. The bear case is heavy reliance on one drug facing a patent cliff later this decade, plus pipeline and regulatory risk. Weigh both against your portfolio.

Exelixis is a commercial-stage oncology company that discovers, develops, and sells cancer drugs. Its business centers on cabozantinib, sold as CABOMETYX, a tyrosine kinase inhibitor approved in cancers including advanced kidney cancer and certain neuroendocrine tumors. Unlike many biotechs, it is profitable, and it is developing a next-generation molecule, zanzalintinib, to extend its franchise.

Cabozantinib, marketed as CABOMETYX, generates the large majority of Exelixis's revenue, making it a concentrated single-franchise company. That concentration boosts profitability when the drug grows but raises risk, because a competitive, safety, or reimbursement setback in kidney cancer would affect the whole business. Reducing this reliance is exactly why zanzalintinib and label expansion matter so much.